Collegium Pharma (COLL) Misses Q4 EPS by $1.77
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results
February 24, 2022 4:01 PM ESTBDSI Acquisition Expected to Close Late Q1 2022
2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER
Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA of $118.3 million
Cash Balance of $186.4 Million
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.... More
